- Home
- HOND vs VYGR Comparison
HOND vs VYGR Comparison
Compare HOND & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- VYGR
- Stock Information
- Founded
- HOND 2024
- VYGR 2013
- Country
- HOND United States
- VYGR United States
- Employees
- HOND N/A
- VYGR N/A
- Industry
- HOND
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- HOND
- VYGR Health Care
- Exchange
- HOND NYSE
- VYGR Nasdaq
- Market Cap
- HOND 334.9M
- VYGR 172.6M
- IPO Year
- HOND 2024
- VYGR 2015
- Fundamental
- Price
- HOND $11.17
- VYGR $3.18
- Analyst Decision
- HOND
- VYGR Strong Buy
- Analyst Count
- HOND 0
- VYGR 8
- Target Price
- HOND N/A
- VYGR $14.33
- AVG Volume (30 Days)
- HOND 331.5K
- VYGR 671.1K
- Earning Date
- HOND 01-01-0001
- VYGR 08-05-2025
- Dividend Yield
- HOND N/A
- VYGR N/A
- EPS Growth
- HOND N/A
- VYGR N/A
- EPS
- HOND 0.20
- VYGR N/A
- Revenue
- HOND N/A
- VYGR $66,958,000.00
- Revenue This Year
- HOND N/A
- VYGR N/A
- Revenue Next Year
- HOND N/A
- VYGR $78.88
- P/E Ratio
- HOND $54.48
- VYGR N/A
- Revenue Growth
- HOND N/A
- VYGR N/A
- 52 Week Low
- HOND $9.90
- VYGR $2.65
- 52 Week High
- HOND $12.24
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- VYGR 55.64
- Support Level
- HOND N/A
- VYGR $3.36
- Resistance Level
- HOND N/A
- VYGR $3.72
- Average True Range (ATR)
- HOND 0.00
- VYGR 0.18
- MACD
- HOND 0.00
- VYGR 0.05
- Stochastic Oscillator
- HOND 0.00
- VYGR 62.92
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.